Kathryn McCrystal Dahir, MD

Physician, Professor of Medicine

About Dr. Dahir

Dr. Kathryn Dahir received her undergraduate degree from the University of Virginia. She completed medical school at East Virginia Medical School, and completed her Internal Medicine Residency training at Vanderbilt University Medical Center. She then pursued a fellowship in Diabetes, Endocrinology and Metabolism, Vanderbilt University Medical Center (2002-2004). She is a Professor of Medicine in the Division of Endocrinology and Metabolism at the Vanderbilt University Medical Center. She is the founder and is the Course Director for the Endocrinology and Rheumatology Metabolic Bone Fellows conference.

Dr. Dahir's clinical and research interests are calcium- and bone-related disorders including hypophosphatasia, osteogenesis imperfecta, tumor induced osteomalacia, fracture nonunion, hyperparathyroidism, osteoporosis, and rickets. She is the principal investigator for multiple studies for patients with rare skeletal dysplasia including Hypophosphatasia (HPP), Osteogenesis Imperfecta (OI), X-Linked Hypophosphatemic Rickets (XLH) and Fibrous Dysplasia Ossificans Progressiva (FOP). She is an investigator in collaboration with Vanderbilt bioinformatics faculty examining, the significance of adults with both dominant negative mutations for the disorder, hypophosphatasia, and low alkaline phosphatase levels. She has multiple collaborative research endeavors within the Department of Orthopedics, Physical therapy, Audiology and Engineering.

On a national level, Dr. Dahir has served on the Endocrine Society committee as the bone and calcium disorders expert leading the development of the maintenance of certification and ESAP products. She is a board member of the Magic Foundation Scientific Board, the HPP Registry Scientific Advisory Board and has been named a U.S. News and World Report Top Doctor for the past 10 years.


Awards and Recognition
Winner of two Outstanding Abstract Awards at The Endocrine Society ENDO Meeting 2018
Winner of an Outstanding Abstract Awards at The Endocrine Society ENDO Meeting 2019
Key Articles in Peer-Reviewed Journals
Michael P. Whyte, MD; William H McAlister; Fan Zhang; Vinieth N Bijanki; Angela Nenninger; Gary S Gottesman; Elizabeth L Lin; Margaret Huskey; Shenghui Duan; Kathryn Dahir; Steven Mumm. New Explanation For Autosomal Dominant High Bone Mass: Activating Mutation Of Low-Density Lipoprotein Receptor-Related Protein 6; accepted to Bone March 2019
Hillis J, Devin C, Archer K, Dahir K, Stephens B. Metabolic and Endocrine Disorders in Pseudarthrosis. Accepted to Clinical Spine Surgery. December 2018.
Neurological Findings in Hypophosphatasia Patients; Ruey Hu, Juan Colazo, Kathryn Dahir MD, Jill Simmons MD Accepted to Osteopororosis International August 2018
Dahir K, Tilden D, Warner J, Bastarache L, Smith D, Newman J, Simmons J, Black M, Denny J. Rare variants in the gene ALPL that cause hypophosphatasia are strongly associated with ovarian and uterine disorders. Journal of Clinical Endocrinology and Metabolism; https://doi.org/10.1210/jc.2017-02676 April 2018 . Selected for the Endocrine Society Thematic Issue on Rare Endocrine Disorders August 2018.
Dahir K, Tilden D, Warner J, Bastarache L, Smith D, Newman J, Simmons J, Black M, Denny J. Rare variants in the gene ALPL that cause hypophosphatasia are strongly associated with ovarian and uterine disorders. Journal of Clinical Endocrinology and Metabolism; https://doi.org/10.1210/jc.2017-02676 April 2018 . Selected for the Endocrine Society Thematic Issue on Rare Endocrine Disorders August 2018.
Mathews J, Harrary M, Bao S, Dahir K. Parathyroid Carcinoma Presenting as Severe Hyperparathyroidism. Submitted to Clinical Endocrinology. November 2017
Kishnani P, Munns C, Nunes M, Rush E, Arundel P, Bishop N, Dahir K, Fraser W, Harmatz P, Linglart A, Ozono K, Saal H, Seefried L, Ozono K. Monitoring Guidance for Patients With Hypophosphatasia Treated With Asfotase Alfa; 2017 Molecular Genetics and Metabolism. doi.org/10.1016/j.ymgme.2017.07.010. 122(102)4-17 Sep 2017
Dahir KM, Basaria SS, Boelaert K, Collazo-Clavell ML, Dalkin AC, Donner TW, Findling JW, Freda PU, Freel M, Green J, Jagasia S, Jan de Beur SM, Jonklaas J, Tannock LR, Vella AV, Welt C. ESAP 2015: Endocrine Self-Assessment Program. Washington, DC: Endocrine Society; 2015.
Attention deficit/hyperactivity disorder: Association between medication therapy and fracture occurrence. Brandon A. Perry, M.D., Kristin R. Archer, Ph.D., Florent Elefteriou, Ph.D., Jennifer K. Green, M.D., Yanna Song, M.S., Yun Ma, Ph.D., Kathryn M. Dahir, M.D. Osteoporos Int. ;27(3) DOI: 10.1007/s00198-016-3569-8. February 2016
Dahir KM, Dalkin AC, Basaria SS, Collazo-Clavell ML, Donner TW, Findling JW, Freda PU, Freel M, Green J, Jagasia S, Jan de Beur SM, Jonklaas J, Mandel SJ, Tannock LR, Vella AV, Welt C. ESAP 2014: Endocrine Self-Assessment Program. Washington DC; Endocrine Press; 2014.
Hypercalcemia secondary to gastrointestinal stromal tumors: parathyroid hormone-related protein independent mechanism?; Prathima Jasti, M.D., Vipul Tulsi Lakhani, M.D., Alison Woodworth, Ph.D., Kathryn McCrystal Dahir, M.D. Endocr Pract. 19(6):e158-62. Doi:10.4158/EP13102.CR November-December, 2013 Sep 6:1-15.
Sodium Thiosulfate in the Treatment of Nonuremic Calciphylaxis; Ning, Matthew; Dahir, Kathryn; Castellanos, Emily; McGirt, Laura. J Dermatol. 2013Aug;40(8):649-52. Doi: 10.1111/1346-8138.12139. Epub 2013 May 10.
Differentiating Familial Hypocalciuric Hypercalcemia from Primary Hyperparathyroidism; Myrick C. Shinall, Jr., MD, Kathryn McCrystal Dahir, MD, James T. Broome, MD. Endocrine Practice. 19(4):697-702. July-August 2013.
Improved Screening for CFRD Achieved Through Collaboration Between Pediatric and Adult Endocrinology and Pulmonary Providers at The Vanderbilt CF Center: Pediatric CF Program Results: 449. Brown, R. F.; Bremer, A.; Franco, W.; Driskill, C.; Brennan, K.; Vincent, W.; Colvin, K.; Guy, D.; Grisso, A.; Duke, L.; Dahir, K.; Clark, A.; Slovis, B.; Perkett, E. Pediatric Pulmonology. 46(34) Supplement 1:375. October 2011.
Improved Screening for CFRD Achieved Through Collaboration Between Pediatric and Adult Endocrinology and Pulmonary Providers at The Vanderbilt CF Center: Adult CF Program Results: 467. Slovis, B. 1; Guy, D. 1; Dahir, K.1; Franco, W. 2,1; Brown, R. 2; Bremer, A. A. 2; Perkett, E. 2. Pediatric Pulmonology. 46(34), Supplement 1:382, October 2011.
Ectopic ACTH Hyper secretion Due to a Primary Pulmonary Paraganglioma, Kathryn McCrystal Dahir, Adriana L. Gonzalez, Monica P. Revelo, Rafeeq Ahmed, John R. Roberts, and Lewis S. Blevins, Jr. Endocrine Practice. 2004 Sep-Oct; 10(5): 424-8
Treatment of Adult Patients with Congenital Adrenal Hyperplasia Due to 21-Hydroxylase Deficiency: A Clinical Practice Audit, Howard Y. Li, M.D.,Kathryn McCrystal Dahir, M.D. and Lewis S. Blevins, Jr., M.D. Endocrine Practice. 2003 Sep-Oct, 9(5): 347-52
“Bilateral Femoral Neck Fractures Secondary to Hypocalcemic Seizures in a Skeletally Immature Patient”; J.S. Blanco, G. Dahir, K. McCrystal. American Journal of Orthopedics. 1999; 28:187-188
Book Chapters
Post- transplantation bone disease: Prevalence, monitoring, prevention, and management guidelines; Chapter 15. Kathryn Dahir, MD, Brandon Perry, MD, Shubhada Jagasia, MD. Blood and Marrow Transplantation Long Term Management: Prevention and Complications, Bipin N. Savani (Editor) ISBN: 978-1-118-47340-5 414 pages, December 2013, Wiley-Blackwell
Abstracts and Posters
The Clinical Utility of Gene Sequencing in Hypophosphatasia: Lessons from Patients with Two Rare Variants, Daniel Tilden, Jonathan H. Sheehan, John H. Newman, Jens Meiler4, Tony Capra, Jill Simmons, Margo Black, Kathryn Dahir. Presented to the Endocrine Society ENDO Meeting 2019 Winner of the Presidential Poster Presentation Award
The role of the modified performance-oriented mobility assessment tool in the evaluation of gait in adults with hypophosphatasia; Christina Durrough, PT, DPT, NCS, Laura Benton PT, DPT, Kathryn Dahir, MD. Presented to the Endocrine Society ENDO Meeting 2019
FHH3: Identification of a Mutation in AP2S1 Causing Familial Hypocalciuric Hpercalcemia Type 3; Monica Bhanot MD, PhD, Andrea Ramirez MD, and Kathryn Dahir MD Presented to the Endocrine Society ENDO Meeting 2019 Nominated for Presidential Poster Presentation Award
Neurological Findings in Hypophosphatasia Patients; Ruey Hu, Juan Colazo, Kathryn Dahir MD, Jill Simmons MD Presented to the Endocrine Society ENDO Meeting 2018
Neurological Findings in Hypophosphatasia Patients; Ruey Hu, Juan Colazo, Kathryn Dahir MD, Jill Simmons MD Presented to the Endocrine Society ENDO Meeting 2018
Pharmacodynamic Results From a Phase 2a, Randomized, Multicenter, Open-label, Dose-ranging Study of Asfotase Alfa in Adults With Pediatric Hypophosphatasia Lothar Seefried, MD; Priya S. Kishnani, MD; Scott Moseley, MS, MS; Eric Watsky, MD; Michael P. Whyte, MD; Kathryn M. Dahir, MD Presented to the Endocrine Society ENDO Meeting 2018
Nine rare Variants In The Tissue-nonspecific Alkaline Phosphatase (TNSALP) Gene: Refining the Phenotype Of Hypophosphatasia; Dan Tilden MD, Jeremy Warner MD, John Newman MD, Jill Simmons MD, Kathryn Dahir, MD, Presented to The Endocrine Society ENDO Meeting 2018 Winner Outstanding Abstract Award
Nine rare Variants In The Tissue-nonspecific Alkaline Phosphatase (TNSALP) Gene: Refining the Phenotype Of Hypophosphatasia; Dan Tilden MD, Jeremy Warner MD, John Newman MD, Jill Simmons MD, Kathryn Dahir, MD, Presented to The Endocrine Society ENDO Meeting 2018 Winner Outstanding Abstract Award
Rare Variants in the ALPL Gene Are Highly Associated with Ovarian and Uterine Disorders; Kathryn Dahir, MD, Dan Tilden, Jeremy Warner, Lisa Bastarache, Jill Simmons, John Newman, Josh Denny. Presented to The Endocrine Society ENDO Meeting 2018
Denosumab-Associated Loss Of Dental Implants And Suppression Of Alkaline Phosphatase Levels In Patients With And Without Undiagnosed ALPL Gene Variants; Rebecca Morey, Andrea Ramirez, Kathryn Dahir MD, Presented The Endocrine Society ENDO Meeting 2018 Winner Outstanding Abstract Award
Parathyroid Carcinoma Presenting as Severe Hyperparathyroidism; Juliana J Matthews, Shichun Bao, Shimon Harary, Joyce E Johnson, James T. Broome, Kathryn Dahir, MD, Presented at The Endocrine Society ENDO Meeting 2018
Low Serum Alkaline Phosphatase Activity: Using Gene Analysis in the Diagnosis of Osteogenesis Imperfecta; Margaret Burkes MD, Kathryn Dahir, MD, Presented at The Endocrine Society ENDO Meeting 2018
Hypophosphatasia. Dissecting a Family History; Rachel Coleman-Pierron MD, Kathryn Dahir, MD, Presented at the Endocrine Society ENDO Meeting 2017.
Parathyroid Carcinoma Presenting As Severe Hyperparathyroidism; Shimon M Harary, MD, Shichun Bao, MD PhD, James T Broome, MD, Kathryn M Dahir, MD. Endocrine Practice ACE Meeting, 2013
Resistant Hypoglycemia in Gastric Lymphoma with Distal Pancreatectomy in Setting of Recurrent Subcutaneous Octreotide Treatment; Shimon Harary MD,Kathryn McCrystal Dahir MD. Endocrine Practice ACE Meeting, 2013
Metabolic and Endocrine Abnormalities in Spinal Fusion Patients with Pseudoarthrosis; Colin G. Crosby, MD; Kathryn Dahir, MD. Presented at the International Spine/ Orthopaedic Meetings, 2012
Grants and Research Support
Primary Investigator SoftBones Hypophosphatasia Research Grant $25,000. Comprehensive Assessment of Functional Performance in Adolescents and Adults with HPP including 3D Motional Analysis of Gait, 2017.
Primary Investigator Study AA-HPP-208: A Phase 2A, Randomized, Multicenter, Open Label, Pharmacokinetics, And Dose Response Study of Asphotase Alpha in Adult Patients with Pediatric Onset Hypophosphastasia. IRB # 160258
Primary Investigator HPP Registry IRB # 151946
Primary Investigator Study Protocol No. MBPS205. A Phase 2b, Multicentre, Multinational, Placebo-controlled, Double-blind, Dose-findings Study in Adult Patients with Type I, III or IV Osteogenesis Imperfecta Treated with BPS804
Primary Investigator of Impact of Treatment of Asphotase Alpha in Adults Diagnosed with Pediatric-onset HPP – Experience from Two US Centers
Primary Investigator XLH Disease Monitoring Program
Primary Investigator. R2477-FOP-1623. A Randomized, Placebo Controlled Study to Assess the Safety, Tolerability, Pharmacokinetics, and Effects on Heterotopic Bone Formation of REGN2477 in Patients with Fibrous Dysplasia Ossificans Progressiva